Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07590167

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Dyslipidemia Cardiovascular Diseases Dyslipidemias Hypertension Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

19 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit

Exclusion criteria

  • Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
  • Other exclusions applied

Treatment and study plan

AD-231

Drug

AD-231 Oral Tablet

AD-231A, AD-231D and AD-231C

Drug

AD-231A Oral Tablet + AD-231D Oral Tablet + AD-231C Oral Tablet

Primary outcomes

  1. Maximum concentration of drug in plasma (Cmax)

    Time frame: pre-dose to 72 hours

    Cmax

  2. Area under the plasma concentration-time curve during dosing interval (AUCt)

    Time frame: pre-dose to 72 hours

    AUCt

Study contacts

Contact information is provided by the study sponsor or research team.

Dasom KIM

CONTACT

[email protected]

+82-31-891-5572

Sponsors and collaborators

Lead sponsor

Addpharma Inc.

Industry

Registry information

Official study title

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C in Healthy Adult Volunteers

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
May 15, 2026
Registry last updated
May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.